Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer

JDDG - Journal of the German Society of Dermatology

Volumn 3, Issue 1, 2005, Pages 26-32

  Gille, Jens ^a,b   Spieth, Konstanze ^a   Kaufmann, Roland ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Angiogenesis Inhibitors; Anticancer Drug Combinations; Chemotherapy; Clinical trials; Malignant neoplasms

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CELECOXIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; METHOTREXATE; ROFECOXIB; TREOSULFAN; VINBLASTINE;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RESEARCH; CANCER SURVIVAL; CHRONIC DRUG ADMINISTRATION; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG TOXICITY; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LOW DRUG DOSE; MELANOMA; METASTASIS; METRONOMIC CHEMOTHERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR MODEL;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CARCINOMA, RENAL CELL; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE II; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LYMPHOMA, NON-HODGKIN; MALE; MELANOMA; NEOPLASM METASTASIS; NEOPLASMS; OVARIAN NEOPLASMS; PILOT PROJECTS; PROSTATIC NEOPLASMS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 12944279734     PISSN: 16100379     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1439-0353.2005.04048.x     Document Type: Review

References (52)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285(21): 1182-1186.
2. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175(3): 409-416.
3. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2(10): 727-739.
4. Eskens FA. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 2004; 90(1): 1-7.
5. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 1991; 13(1): 31-36.
6. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy, rationale, challenges and clinical studies. Angiogenesis 2002; 5(4): 237-256.
7. McCarty MF, Liu W, Fan F, Parikh A, Reimuth N, Stoeltzing O, Ellis LM. Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends Mol Med 2003; 9(2): 53-58.
8. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9(6): 653-660.
9. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001; 19(4): 1195-1206.
10. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie-Shepherd SR, Folkman J. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001; 61(20): 7669-7674.
11. Kerbel RS, Viloria-Petit A, Klement G, Rak J. 'Accidental' anti-angiogenic drugs, anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000; 36(10): 1248-1257.
12. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4(6): 423-436.
13. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105(8): 1045-1047.
14. Fidler IJ, Ellis LM. Chemotherapeutic drugs - more really is not better. Nat Med 2000; 6(5): 500-502.
15. Kamen BA, Rubin E, Aisner J, Glatstein E. High-time chemotherapy or high time for low dose. J Clin Oncol 2000; 18(16): 2935-2937.
16. Skipper HE, Schabel FM Jr., Mellett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, Brockman RW. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 1970; 54(6): 431-450.
17. Dodwell DJ. Cytotoxic drugs: the search for dose response. Lancet 1993; 341(8845): 614-616.
18. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 1982; 45(1): 136-139.
19. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A, Dammacco F. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999; 94(12): 4143-4155.
20. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002; 62(23): 6938-6943.
21. Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anti-cancer Drugs 2003; 14(1): 13-19.
22. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60(7): 1878-1886.
23. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105(8): R15-R24.
24. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997; 24(4 Suppl 10): 3-10.
25. Hainsworth JD, Burns HA, III, Greco FA. Weekly administration of docetaxel (Taxotere): summary of clinical data. Semin Oncol 1999; 26(3 Suppl 10): 19-24.
26. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18(6): 1212-1219.
27. Link MP, Shuster JJ, Donaldson SS, Berard CW, Murphy SB. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med 1997; 337(18): 1259-1266.
28. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001; 19(12): 3091-3102.
29. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de BF, Viale G, Goldhirsch A. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13(1): 73-80.
30. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60(5): 1306-1311.
31. Onn A, Tseng JE, Herbst RS. Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy. Clin Cancer Res 2001; 7(11): 3311-3313.
32. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4(4): 314-322.
33. Spieth K, Kaufmann R, Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol 2003; 52(5): 377-382.
34. Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, Nova P, Aglione S, Taillibert S, Khayat D. Metastatic melanoma: chemotherapy. Semin Oncol 2002; 29(5): 427-445.
35. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemothetapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11(1): 75-81.
36. Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2001; 2(12): 733-740.
37. DiPaola RS, Durivage HJ, Kamen BA. High time for low-dose prospective clinical trials. Cancer 2003; 98(8): 1559-1561.
38. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4(4): 253-265.
39. Fidler IJ. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst 2001; 93(14): 1040-1041.
40. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411(6835): 375-379.
41. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420(6917): 860-867.
42. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-2342.
43. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler IJ. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60(11): 2926-2935.
44. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151(6): 1523-1530.
45. Rak J, Yu JL, Kerbel RS, Coomber BL. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res 2002; 62(7): 1931-1934.
46. Kakeji Y, Teicher BA. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997; 15(1): 39-48.
47. Orlando L, Colleoni M, Bertolini F, Ghiaini R, Sanna G, Formica V, Nolè F, Viale G, Franceschelli L, Goldhirsch A. Metronomic oral chemotherapy (CT) versus the same regimen in association with Thalidomide (TLM): Results of a randomized trial in patients (pts) with advanced breast cancer (ABC). Proc Am Soc Clin Oncol 2004; 23: A3015.
48. Young SD, Germond CJ, Noble JC, Cano PO, Lopez PG. A phase II clinical trial involving the use of low-dose daily oral cyclophosphamide, weekly vinblastine and rofecoxib in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2004; 23: A3137.
49. Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone tor prostate carcinoma. Cancer 2003; 98(8): 1643-1648.
50. Bjarnason GA, Krzyzanowska MK, Knox J, Moore M, Lockwood G, Ho C, Tannock I. Phase II trial of continuous low dose cyclophosphamide and celecoxib in patients with progressing advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2003; 22: A1717.
51. Buckstein R, Crump M, Shaked Y, Foden C, Nayar R, Taylor D, Bertolini F, Baruchel S, Man S, Kerbel R. Palliation of relapsed aggressive histology NHL with high-dose celecoxib and 'metronomic' low-dose cyclophosphamide. Proc Am Soc Clin Oncol 2004; 23: A3016.
52. Gluck S, Mackinnon J, Lau H, Syme R, Dort J, Gluck D. Metronomic therapy in recurrent and metastatic chemo-resistant SCCHN: Data from a pilot study. Proc Am Soc Clin Oncol 2003; 22: A2066.